A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

NCT04844918 on ClinicalTrials.gov · last registry update 2024-07-16

Finished 24 June 2023, after enrolling 267 people. Primary outcome, as filed: Mean Percent Change in Body Weight. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 267
Started: 2021-05-10
Primary completion: 2023-06-24 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Percent Change in Body Weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.